Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis

Alsaad, Noor; Altena, Richard van; Pranger, Arianna D.; Soolingen, Dick van; Lange, Wiel C M de; Werf, Tjip S. van der; Kosterink, Jos G. W.; Alffenaar, Jan‐Willem C.

doi:10.1183/09031936.00114812

Cited by 56 publications

(59 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a cost reduction could even contribute to the call for making global MDR-TB control affordable [32]. Further research on WHO group 5 drugs such as linezolid, besides evaluation of new drugs such as delaminid [33] or old drugs such as co-trimoxazole [34], is of great importance.…”

Section: Discussionmentioning

confidence: 99%

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

The use of linezolid for the treatment of multidrug-resistant tuberculosis is limited by doseand time-dependent toxicity. Recently, we reported a case of pharmacokinetic drug-drug interaction between linezolid and clarithromycin that resulted in increased linezolid exposure. The aim of this prospective pharmacokinetic study is to quantify the effect of clarithromycin on the exposure of linezolid.Subjects were included in an open-label, single-centre, single-arm, fixed-order pharmacokinetic interaction study. All subjects received 300 mg linezolid twice daily during the entire study, consecutively co-administered with 250 mg and 500 mg clarithromycin once daily. Steady-state serum curves of linezolid and clarithromycin were analysed using validated methods, and differences between pharmacokinetic parameters were calculated.Linezolid exposure increased by a median (interquartile range) of 44% (23-102%, p50.043) after coadministration of 500 mg clarithromycin (n55) compared to baseline, whereas 250 mg clarithromycin had no statistically significant effect. Co-administration was well tolerated by most patients; none experienced severe adverse effects. One patient reported common toxicity criteria grade 2 gastrointestinal adverse events.In this study, we showed that clarithromycin significantly increased linezolid serum exposure after combining clarithromycin with linezolid in multidrug-resistant tuberculosis patients. The drug-drug interaction is possibly P-glycoprotein-mediated. Due to large interpatient variability, therapeutic drug monitoring is advisable to determine individual effect size. @ERSpublications Clarithromycin significantly increased linezolid serum exposure in multidrug-resistant tuberculosis patients

show abstract

Section: Discussionmentioning

confidence: 99%

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…As it must be recognised, following current trends, Europe is unlikely to achieve elimination of the disease by the target date of 2050 [23,24], we urgently need new vaccines, as well as improved diagnostics [25,26] and new drugs [27][28][29]. With respect to economic considerations, the aim of the present study was to evaluate the costs associated with TB disease in order to determine whether they outweigh the investment needed to generate a new vaccine.…”

Section: Introductionmentioning

confidence: 99%

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

Diel

Vandeputte²,

Vries

et al. 2013

European Respiratory Journal

157

131

View full text Add to dashboard Cite

Without better vaccines it is unlikely that tuberculosis (TB) will ever be eliminated. An investment of ,J560 million is considered necessary to develop a new, effective vaccine in the European Union (EU). However, less is known about the costs of TB disease in the EU. We performed a systematic review of literature and institutional websites addressing the 27 EU members to summarise cost data. We searched MEDLINE, EMBASE and Cochrane bibliographies for relevant articles.Combining direct and indirect costs, we arrived at an average per-TB case costs in the original EU-15 states plus Cyprus, Malta and Slovenia of J10 282 for drug-susceptible TB, J57 213 for multidrug resistant (MDR)-TB and J170 744 for extensively drug resistant (XDR)-TB. In the remaining new EU states, costs amounted to J3427 for drug-susceptible TB and J24 166 for MDR-TB/XDR-TB. For the 70 340 susceptible TB cases, 1488 MDR-TB and 136 XDR-TB cases notified in 2011 costs of J536 890 315 accumulated in 2012. In the same year, the 103 104 disability-adjusted life years caused by these cases, when stated in monetary terms, amounted to a total of J5 361 408 000.Thus, the resulting economic burden of TB in the EU clearly outweighs the cost of investing in more efficient vaccines against TB. @ERSpublications The economic burden of tuberculosis in the EU outweights the cost of investing in more efficient vaccines against tuberculosis

show abstract

“…Other drugs, including sulfamides and mefloquine, have been used in difficult-to-treat cases, although the evidence is anecdotal [63][64][65] . OBR: optimized background regimen; C: culture; HR: hazard ratio; CI: confidence interval; CFU: colony-forming unit; SS: sputum smear; AE: adverse events; BCI: Bayesian credibility interval; BID: twice daily; QT: measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; ECG: electrocardiogram; EBA: early bactericidal activity; DS: drug-susceptible; DR: drug-resistant; MDR-TB: multidrug-resistant tuberculosis; PTB: pulmonary tuberculosis; DR-TB: drug-resistant-tuberculosis; TB: tuberculosis; WBA: whole blood bactericidal activity; OB: once daily; MIC: minimum inhibitory concentration; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; Bql: bedaquiline; Pto: pretomanid; Del: delamanid; Cfz: cloafazimine.…”

Section: Re-proposed Drugsmentioning

confidence: 99%

Pulmonary Tuberculosis Management: 2015 Update

D’Ambrosio¹,

Centis²,

Mantero³

et al. 2015

BRN

View full text Add to dashboard Cite

Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis

Cited by 56 publications

References 30 publications

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

Pulmonary Tuberculosis Management: 2015 Update

Contact Info

Product

Resources

About